Download Free Sample
Author
Manoj Kumar is a postgraduate in Life Sciences with over seven years of dedicated experience in the fields of anima.....
Veterinary Cancer Therapeutics Market: By Product, By Cancer, By Species and Geography
Veterinary Cancer Therapeutics Market: By Product, By Cancer, By Species and Geography
Veterinary Cancer Therapeutics Market size was valued at US$ 288.2 million in 2023 and is expected to grow at a CAGR of 11.6% from 2024 to 2030. The global market provides a detailed overview of the market, and that can be segmented by product, by cancer, and by Species. By product, the market has been segmented into Chemotherapeutic Agents, Vaccines, and Others. The chemotherapy segment is likely to be the largest and fastest-growing segment in terms of product. The rise of this segment is mainly due to the growing number of chemotherapeutic events accepted by surgeons owing to the several advantages. As per the oncology guidelines by AAHA, chemotherapy is a frequently used mode of veterinary oncology treatment in veterinary cancer medication.
Moreover, other chemotherapy approaches for example conventional, targeted chemotherapy such as Tyrosine Kinase Inhibitors and metronomic are accepted by small animal doctors. Based on Cancer, the market is segmented into Mast Cell Tumors, Lymphoma, Insulinomas, Chondrosarcoma, and Others. Among these, the lymphoma cancer segment is expected to have the fastest-growing market during the forecast period. The rise of this segment is mainly due to the growing number of the pet population, particularly canines, being suffered by the disease.
Moreover, the rising incidence of cancer in this populace has further involved scientists in comparative veterinary oncology treatment with many clinical trials on dogs as a biological model. As per a PubMed report, an assessed incidence rate of 20-100 cases per 100,000 dogs suffered from this disease. Based on the Species, the Veterinary Cancer Therapeutics market is segmented into Bovine, Porcine, Cats, Dogs, and Others. The dogs segment is expected to have a significant share in 2022. The rise of this segment is mainly because of the increasing prevalence of cancer in the dog population and growing life expectancy.
Study Period
2024-2030Base Year
2023CAGR
11.6%Largest Market
North AmericaFastest Growing Market
North America
The rise in the prevalence of cancer in animals, particularly in pets, along with the rise in R&D investment by businesses to generate cancer therapeutics, such as chemotherapeutic agents and preventive vaccines, are anticipated to propel the market growth over the forecast years. Moreover, an increase in animal health expenditure and a vigorous animal cancer pipeline are burgeoning the market growth over the forecast years.
North America market is expected to witness the highest market share during the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 288.2 million |
|
Market CAGR |
11.6% |
|
By Product |
|
|
By Cancer |
|
|
By Species |
|
|
By Region |
|
Download Free Sample Report
The global veterinary cancer therapeutics market size was valued at US$ 288.2 million in 2023 and is projected to grow at a CAGR of 11.6% from 2024 to 2030.
Merial (C.H. BoehringerSohn AG &Ko. KG) (Germany), Zoetis Inc. (U.S.), AB Science (France), Aratana Therapeutics (U.S.), Oasmia Pharmaceutical (Sweden), Vetivax (U.S.), Regeneus (Australia)
North America is the fastest-growing region for veterinary cancer therapeutics market
| 1.Executive Summary |
| 2.Global Veterinary Cancer Therapeutics Market Introduction |
| 2.1.Global Veterinary Cancer Therapeutics Market - Taxonomy |
| 2.2.Global Veterinary Cancer Therapeutics Market - Definitions |
| 2.2.1. By Product Type |
| 2.2.2. By Cancer |
| 2.2.3. By Species |
| 2.2.4. By Region |
| 3.Global Veterinary Cancer Therapeutics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Veterinary Cancer Therapeutics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Veterinary Cancer Therapeutics Market By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Chemotherapeutic Agent |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Vaccine |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global Veterinary Cancer Therapeutics Market By Cancer, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Mast Cell Tumors |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Lymphoma |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Insulinomas |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Chondrosarcoma |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Veterinary Cancer Therapeutics Market By Species, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Bovine |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Porcine |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Cats |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Dogs |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Others |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.Global Veterinary Cancer Therapeutics Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Veterinary Cancer Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Chemotherapeutic Agent |
| 9.1.2.Vaccine |
| 9.1.3.Others |
| 9.2. Cancer Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Mast Cell Tumors |
| 9.2.2.Lymphoma |
| 9.2.3.Insulinomas |
| 9.2.4.Chondrosarcoma |
| 9.2.5.Others |
| 9.3. Species Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Bovine |
| 9.3.2.Porcine |
| 9.3.3.Cats |
| 9.3.4.Dogs |
| 9.3.5.Others |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Veterinary Cancer Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Chemotherapeutic Agent |
| 10.1.2.Vaccine |
| 10.1.3.Others |
| 10.2. Cancer Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Mast Cell Tumors |
| 10.2.2.Lymphoma |
| 10.2.3.Insulinomas |
| 10.2.4.Chondrosarcoma |
| 10.2.5.Others |
| 10.3. Species Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Bovine |
| 10.3.2.Porcine |
| 10.3.3.Cats |
| 10.3.4.Dogs |
| 10.3.5.Others |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Veterinary Cancer Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Chemotherapeutic Agent |
| 11.1.2.Vaccine |
| 11.1.3.Others |
| 11.2. Cancer Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Mast Cell Tumors |
| 11.2.2.Lymphoma |
| 11.2.3.Insulinomas |
| 11.2.4.Chondrosarcoma |
| 11.2.5.Others |
| 11.3. Species Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Bovine |
| 11.3.2.Porcine |
| 11.3.3.Cats |
| 11.3.4.Dogs |
| 11.3.5.Others |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Veterinary Cancer Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Chemotherapeutic Agent |
| 12.1.2.Vaccine |
| 12.1.3.Others |
| 12.2. Cancer Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Mast Cell Tumors |
| 12.2.2.Lymphoma |
| 12.2.3.Insulinomas |
| 12.2.4.Chondrosarcoma |
| 12.2.5.Others |
| 12.3. Species Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Bovine |
| 12.3.2.Porcine |
| 12.3.3.Cats |
| 12.3.4.Dogs |
| 12.3.5.Others |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Veterinary Cancer Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Chemotherapeutic Agent |
| 13.1.2.Vaccine |
| 13.1.3.Others |
| 13.2. Cancer Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Mast Cell Tumors |
| 13.2.2.Lymphoma |
| 13.2.3.Insulinomas |
| 13.2.4.Chondrosarcoma |
| 13.2.5.Others |
| 13.3. Species Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Bovine |
| 13.3.2.Porcine |
| 13.3.3.Cats |
| 13.3.4.Dogs |
| 13.3.5.Others |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.AB Science (France) |
| 14.2.2.Aratana Therapeutics (U.S.) |
| 14.2.3.Oasmia Pharmaceutical (Sweden) |
| 14.2.4.Vetivax (U.S.) |
| 14.2.5.Regeneus (Australia) |
| 14.2.6.Zoetis Inc. (U.S.) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Manoj Kumar is a postgraduate in Life Sciences with over seven years of dedicated experience in the fields of animal health and agriculture. His passion lies in unraveling the complexities of these domains through rigorous research and practical insights. Manoj Kumar’s journey has been marked by several key achievements: as a market analyst and competitive intelligence expert, he dissects data to provide actionable insights for global clients. Simultaneously, he champions animal healthcare, diagnosing ailments, and designing preventive care strategies. In the realm of agriculture, his focus on sustainable practices, emphasizing crop nutrition, soil health, and precision agriculture. His holistic approach and commitment to advancing science make him a respected figure in the ever-evolving landscape of life sciences.